Video yükleniyor...

Video Yüklenemedi

Bu video yüklenirken bir sorun oluştu. Bu geçici bir ağ sorunundan kaynaklanıyor olabilir veya video kullanılamıyor olabilir.

Ana Sayfaya Dön

The one shot longevity solution is around the corner. Crémieux casually mentioned on Health Care Network this week that there’s a PCSK9 + GLP-1 fusion drug already in development. Add a BP agent and you’ve knocked out ~90% of what actually kills people. What’s actually in the pipeline right... show more

Dr Danish

46,887 subscribers

17,890 görüntüleme • 2 ay önce •via X (Twitter)

Bilim & Teknoloji Sağlık & İyilik

Anya Rossi• Live Now

Private livecam show

14 Yorum

Cédric Kovacs-Johnson profil fotoğrafı

Cédric Kovacs-Johnson2 ay önce

@cremieuxrecueil @watchhcn Lmao we’re all gonna look the same at 150 yrs old

Dr Danish profil fotoğrafı

Dr Danish2 ay önce

@cremieuxrecueil @watchhcn you’ll have more hair

Gone profil fotoğrafı

Gone2 ay önce

@cremieuxrecueil @watchhcn Add in an anti myostatin drug to deal with muscle loss and you're golden.

Dr Danish profil fotoğrafı

Dr Danish2 ay önce

@cremieuxrecueil @watchhcn 100%

Arham profil fotoğrafı

Arham2 ay önce

@cremieuxrecueil @watchhcn This is garbage. Absolute nonsense. Anti scientific. Pathetic. Lipids do not kill people.

Dr Danish profil fotoğrafı

Dr Danish2 ay önce

@cremieuxrecueil @watchhcn hilariously incorrect.

Arham profil fotoğrafı

Arham2 ay önce

@cremieuxrecueil @watchhcn Provide cause and effect evidence lipids cause disease. It does not exist. Do you have it?

Dr Danish profil fotoğrafı

Dr Danish2 ay önce

@cremieuxrecueil @watchhcn @cremieuxrecueil has like a million tweets on this.

Crémieux profil fotoğrafı

Crémieux2 ay önce

@arhamgrowthcap @watchhcn

Arham profil fotoğrafı

Arham2 ay önce

@operationdanish @watchhcn How many measurements of blood lipids (x axis) per subject in his graph?

Crémieux profil fotoğrafı

Crémieux2 ay önce

@operationdanish @watchhcn Depends on the particular study. Click in if you'd like to learn more. The causal evidence is totally unambiguous and leaves no room for doubt.

Arham profil fotoğrafı

Arham2 ay önce

@operationdanish @watchhcn Nobody said anything of substance. One guy said hey this other guy has posts on this. That guy says go look at it instead of answering critiques (many times). Both have hands over their ears and say just believe me. illustration of what goes on when u have no scientific integrity

Brett Hudson | Zyndio profil fotoğrafı

Brett Hudson | Zyndio2 ay önce

A PCSK9 plus GLP-1 fusion drug is a massive development. Addressing LDL, glycemia, and weight in one injection could reshape longevity medicine. But the real opportunity is pairing these tools with biomarker education so people understand what their numbers mean and why these interventions matter. At we believe informed patients make the best decisions. God Bless the researchers pushing this forward 🙏

Valar Research profil fotoğrafı

Valar Research2 ay önce

@cremieuxrecueil @watchhcn The really interesting question is whether combining these targets creates true synergy or just pharmacologic convenience. The cardiovascular outcome data will matter far more than the number of pathways one molecule hits.

Benzer Videolar

🚨GLP-1: “It’s Not That Simple”💉 1/4) There are many strong, often dogmatic, opinions on GLP-1 receptor agonists. One interesting, and under-appreciated, fact is that GLP-1 aren’t "just" weight loss drugs. They have complex metabolic effects, including reducing whole body inflammation by acting on the brain, partly in a weight-loss independent manner. GLP-1 receptor agonists, and related medications, can help people but can also be misused at a societal level. Let me elaborate (link 🔗 at the end)... #GLP1 #inflammation

🚨GLP-1: “It’s Not That Simple”💉 1/4) There are many strong, often dogmatic, opinions on GLP-1 receptor agonists. One interesting, and under-appreciated, fact is that GLP-1 aren’t "just" weight loss drugs. They have complex metabolic effects, including reducing whole body inflammation by acting on the brain, partly in a weight-loss independent manner. GLP-1 receptor agonists, and related medications, can help people but can also be misused at a societal level. Let me elaborate (link 🔗 at the end)... #GLP1 #inflammation

Nick Norwitz MD PhD

13,704 görüntüleme • 1 yıl önce

“We’re seeing this in our clinic now…people are GAINING weight on GLP-1 medications.”

“We’re seeing this in our clinic now…people are GAINING weight on GLP-1 medications.”

DoctorTro

120,985 görüntüleme • 1 ay önce

“We’re seeing this in our clinic now…people are GAINING weight on GLP-1 medications.”

“We’re seeing this in our clinic now…people are GAINING weight on GLP-1 medications.”

DoctorTro

315,690 görüntüleme • 11 ay önce

NEW: Andrew Huberman warns high-dose GLP-1s can suppress ambition and drive, not just appetite. "They bind to these hypothalamic and other areas... that activate neurons that are involved in the suppression of appetite. And so it's a very simple equation really. Ramp these GLP levels up thousandfold, people aren't as hungry. But turns out they're not as driven for other things too if you get beyond a certain level." Hunger and ambition run on overlapping brain circuitry, so a drug that turns one down can turn down the other. Roughly 1 in 9 American adults is now on a GLP-1 for weight loss, per Gallup.

NEW: Andrew Huberman warns high-dose GLP-1s can suppress ambition and drive, not just appetite. "They bind to these hypothalamic and other areas... that activate neurons that are involved in the suppression of appetite. And so it's a very simple equation really. Ramp these GLP levels up thousandfold, people aren't as hungry. But turns out they're not as driven for other things too if you get beyond a certain level." Hunger and ambition run on overlapping brain circuitry, so a drug that turns one down can turn down the other. Roughly 1 in 9 American adults is now on a GLP-1 for weight loss, per Gallup.

KanekoaTheGreat

38,170 görüntüleme • 1 ay önce

Alex Karnal (Alex Karnal) is the most talented bio and healthcare investor I've ever met. He's spent 20 years in the industry and says 2025 was the single most exciting year he's seen. The start of a once-in-a-lifetime, trillion-dollar revolution in public health. He explains how few people realize we already have the medicines to prevent our deadliest diseases. The problem is that almost no one takes them. There's a population of people born with a mutation that means their bodies don't produce a protein called PCSK9. Their lifetime risk of cardiovascular disease is 88% lower than yours. Pharma turned that genetic advantage into a drug. It's been approved for years, but the number of people taking it is still vanishingly small. Partly because high cholesterol is a silent killer. You feel nothing, right up until you have a heart attack. And partly because the health system makes it punishingly hard to stay on a preventive drug like a PCSK9 inhibitor. In other words, the medicine works, but the system around it doesn't. That's what's starting to change, and in this episode, Alex explains why. We discuss the "health stack" he believes can add a decade to most lives, why oral GLP-1s are breaking every adoption record in pharma, peptides and citizen pharmacology, and what AI is doing to drug discovery. I wish I had an "Alex" for every interesting topic. We've been having versions of this conversation for over five years, and every single one is as clear and as useful as this one. Enjoy! Timestamps: 0:00 Intro 1:00 The State of Modern Medicine 5:00 Designing the Modern Health Stack 12:17 The GLP-1 Inflection Point 19:18 The Biological Mechanisms of GLP-1 30:36 Overcoming Frictions in Healthcare 34:19 Cardiovascular Disease 44:04 Addressing Alzheimer's 47:04 The Future of Cancer 57:33 Drug Discovery 1:05:25 AI and Scientific Super Intelligence 1:14:40 Citizen Pharmacology and the Peptide Movement 1:18:13 Background and Career Journey 1:31:09 Braidwell's Investment Approach 1:33:30 The Kindest Thing

Alex Karnal (Alex Karnal) is the most talented bio and healthcare investor I've ever met. He's spent 20 years in the industry and says 2025 was the single most exciting year he's seen. The start of a once-in-a-lifetime, trillion-dollar revolution in public health. He explains how few people realize we already have the medicines to prevent our deadliest diseases. The problem is that almost no one takes them. There's a population of people born with a mutation that means their bodies don't produce a protein called PCSK9. Their lifetime risk of cardiovascular disease is 88% lower than yours. Pharma turned that genetic advantage into a drug. It's been approved for years, but the number of people taking it is still vanishingly small. Partly because high cholesterol is a silent killer. You feel nothing, right up until you have a heart attack. And partly because the health system makes it punishingly hard to stay on a preventive drug like a PCSK9 inhibitor. In other words, the medicine works, but the system around it doesn't. That's what's starting to change, and in this episode, Alex explains why. We discuss the "health stack" he believes can add a decade to most lives, why oral GLP-1s are breaking every adoption record in pharma, peptides and citizen pharmacology, and what AI is doing to drug discovery. I wish I had an "Alex" for every interesting topic. We've been having versions of this conversation for over five years, and every single one is as clear and as useful as this one. Enjoy! Timestamps: 0:00 Intro 1:00 The State of Modern Medicine 5:00 Designing the Modern Health Stack 12:17 The GLP-1 Inflection Point 19:18 The Biological Mechanisms of GLP-1 30:36 Overcoming Frictions in Healthcare 34:19 Cardiovascular Disease 44:04 Addressing Alzheimer's 47:04 The Future of Cancer 57:33 Drug Discovery 1:05:25 AI and Scientific Super Intelligence 1:14:40 Citizen Pharmacology and the Peptide Movement 1:18:13 Background and Career Journey 1:31:09 Braidwell's Investment Approach 1:33:30 The Kindest Thing

Patrick OShaughnessy

679,696 görüntüleme • 6 ay önce

"Finally. Gentle Relief for GLP-1 Users." This brand is printing. GLP-1 SOS Supplements. 109 active ads. Problem-aware hook that speaks directly to a massive side effect nobody talks about. "Stuck on the toilet with GLP-1?" — instantly qualifies the reader. If you're on Ozempic or Mounjaro, you FELT that line in your gut. Most supplement brands sell benefits. GLP-1 SOS sells relief from a specific, embarrassing problem. The GLP-1 market is exploding but nobody's solving the side effects. This brand owns that gap entirely. NOW GO FUCKING PRINT 🔥 I use gethookd.ai to spy on 70M+ winning ads. They scrape 110,000+ brands daily on Facebook.

Henry

10,500 görüntüleme • 7 ay önce

WIFE 'EMBARRASSED' TO TELL SPOUSE SHE’S ON GLP-1: A woman wrote to ‘The Washington Post’ advice column saying she hasn’t told her husband she’s taking a GLP-1 weight-loss drug — ‘The View’ co-hosts weigh in.

WIFE 'EMBARRASSED' TO TELL SPOUSE SHE’S ON GLP-1: A woman wrote to ‘The Washington Post’ advice column saying she hasn’t told her husband she’s taking a GLP-1 weight-loss drug — ‘The View’ co-hosts weigh in.

The View

23,373 görüntüleme • 4 ay önce

JUST IN: President Trump announced a deal with drug companies Eli Lilly and Novo Nordisk to lower costs for many Americans on GLP-1 weight loss drugs on Thursday.

JUST IN: President Trump announced a deal with drug companies Eli Lilly and Novo Nordisk to lower costs for many Americans on GLP-1 weight loss drugs on Thursday.

ABC News

34,155 görüntüleme • 1 yıl önce

The GLP-1 peptide market is doing $60B in annual revenue. That's roughly what OpenAI and Anthropic are pulling in combined. One molecule class. And manufacturing still can't keep up with demand. Aaron Weaver on why peptides are the most underpriced category in biotech right now.

The GLP-1 peptide market is doing $60B in annual revenue. That's roughly what OpenAI and Anthropic are pulling in combined. One molecule class. And manufacturing still can't keep up with demand. Aaron Weaver on why peptides are the most underpriced category in biotech right now.

PeptAI

12,001 görüntüleme • 5 ay önce

The FDA has approved the first pill form of Wegovy, a GLP-1 drug for weight loss. Sophie Flay reports.

The FDA has approved the first pill form of Wegovy, a GLP-1 drug for weight loss. Sophie Flay reports.

Good Morning America

14,658 görüntüleme • 10 ay önce

What can GLP-1 drugs teach us about aging? In this video, I share new NIH-funded research showing that semaglutide, a GLP-1 medication, extended lifespan and improved several measures of health in older mice. While more research is needed to understand what these findings could mean for people, the study offers intriguing insights into the biology of aging. Learn more:

What can GLP-1 drugs teach us about aging? In this video, I share new NIH-funded research showing that semaglutide, a GLP-1 medication, extended lifespan and improved several measures of health in older mice. While more research is needed to understand what these findings could mean for people, the study offers intriguing insights into the biology of aging. Learn more:

Jay Bhattacharya, MD, PhD

189,622 görüntüleme • 1 ay önce

How the PCSK9 inhibitor, enlicitide, lowers LDL cholesterol:

How the PCSK9 inhibitor, enlicitide, lowers LDL cholesterol:

Samuel Hume

20,709 görüntüleme • 1 ay önce

1 in 10 people globally interact with AI weekly. 1 IN 8 AMERICANS ARE ON A GLP-1. Finally, healthcare DEFLATION. While AI is reshaping how we do things, GLP-1s are reshaping human biology. And their convergence offers something the US healthcare system has never experienced in its entire history. As Eric Larsen points out, this is not a trend. This is a restructuring of humanity. eMed

1 in 10 people globally interact with AI weekly. 1 IN 8 AMERICANS ARE ON A GLP-1. Finally, healthcare DEFLATION. While AI is reshaping how we do things, GLP-1s are reshaping human biology. And their convergence offers something the US healthcare system has never experienced in its entire history. As Eric Larsen points out, this is not a trend. This is a restructuring of humanity. eMed

Linda Yaccarino

20,214 görüntüleme • 4 ay önce

Costs are prompting some employers to stop offering group health insurance coverage. KFF's Cynthia Cox says coverage of GLP-1 diabetes and weight loss drugs is one reason for the rise in costs.

Costs are prompting some employers to stop offering group health insurance coverage. KFF's Cynthia Cox says coverage of GLP-1 diabetes and weight loss drugs is one reason for the rise in costs.

Squawk Box

27,445 görüntüleme • 2 ay önce

There's a class of drugs called PCSK9 inhibitors that few people have heard of but Alex thinks will be far bigger than GLP-1s (which is already one of the best selling drugs of all time). They were discovered through a population born with a genetic mutation that gives them an 88% lifetime reduction in cardiovascular disease risk. The drugs mimic that mutation, significantly lowering our bad cholesterol and reducing the risk of a future heart attack or stroke. Alex describes them as close to a free lunch as there is in biology. "Because it is more asymmetric, it is more of a free lunch, I would argue that this medicine should be far bigger in terms of the number of people that are on it and the revenues associated with it than GLP-1s."

There's a class of drugs called PCSK9 inhibitors that few people have heard of but Alex thinks will be far bigger than GLP-1s (which is already one of the best selling drugs of all time). They were discovered through a population born with a genetic mutation that gives them an 88% lifetime reduction in cardiovascular disease risk. The drugs mimic that mutation, significantly lowering our bad cholesterol and reducing the risk of a future heart attack or stroke. Alex describes them as close to a free lunch as there is in biology. "Because it is more asymmetric, it is more of a free lunch, I would argue that this medicine should be far bigger in terms of the number of people that are on it and the revenues associated with it than GLP-1s."

Patrick OShaughnessy

223,727 görüntüleme • 6 ay önce

GLP-1 Receptor Agonists are one of the most revolutionary new classes of drugs in decades. By now, their benefits for #weightmanagement, controlling blood glucose, treating #Type2Diabetes , improving #cardiovascular health, and more are widely known. But what role should they play in the global #obesity crisis? In a new episode of #HealthyDialogue, Lotte Bjerre Knudsen, DMSc, who won the Lasker Award for her pioneering work developing the first long-acting GLP-1RAs, and Jens Juul Holst, MD, DMSc, discuss the discovery and development of these drugs and answer the question, "should everyone be on GLP-1s?" 📖 Read full article to learn more:

GLP-1 Receptor Agonists are one of the most revolutionary new classes of drugs in decades. By now, their benefits for #weightmanagement, controlling blood glucose, treating #Type2Diabetes , improving #cardiovascular health, and more are widely known. But what role should they play in the global #obesity crisis? In a new episode of #HealthyDialogue, Lotte Bjerre Knudsen, DMSc, who won the Lasker Award for her pioneering work developing the first long-acting GLP-1RAs, and Jens Juul Holst, MD, DMSc, discuss the discovery and development of these drugs and answer the question, "should everyone be on GLP-1s?" 📖 Read full article to learn more:

JAMA

13,994 görüntüleme • 2 ay önce

In 2026, 1 in 10 Americans are on weight-loss drugs. But they are affecting the American economy in ways no one expected. 6 of the wildest side-effects of GLP-1s: 1. Airlines saving $580M/year in jet fuel because passengers are lighter

In 2026, 1 in 10 Americans are on weight-loss drugs. But they are affecting the American economy in ways no one expected. 6 of the wildest side-effects of GLP-1s: 1. Airlines saving $580M/year in jet fuel because passengers are lighter

Frank Curzio

1,188,940 görüntüleme • 3 ay önce

This week on the Wellness, Actually podcast, Emily Oster and I dig into GLP-1s. But like... deep into GLP-1s. First let's dispel a myth I see around here a lot that weight loss through diet and exercise is somehow more permanent. Um... no.

This week on the Wellness, Actually podcast, Emily Oster and I dig into GLP-1s. But like... deep into GLP-1s. First let's dispel a myth I see around here a lot that weight loss through diet and exercise is somehow more permanent. Um... no.

F. Perry Wilson, MD MSCE

24,263 görüntüleme • 8 ay önce